Antithrombotic Therapy and Mortality Risk in Older Adults with Hip Fractures
Journal of the American Medical Directors Association · 2025
DOI: 10.1016/j.jamda.2025.105690 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Medical Directors Association, 2025. Verfasst von Karin Vleeshouwers und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of General Internal Medicine, Department of Internal Medicine, Section Geriatric Medicine, Maastricht University Medical Center+, Maastricht…. Hauptthemen laut MEDLINE: Hip Fractures, Fibrinolytic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Gerontologische Pflege
Abstract (Originalsprache)
OBJECTIVES: Antithrombotic therapy, including antiplatelet therapy, direct oral anticoagulants (DOACs), and vitamin K antagonists (VKAs), is increasingly prescribed. These therapies pose complex challenges in patients with hip fracture due to risks of bleeding, risks of thromboembolism, and their potential role as markers of frailty. However, limited real-world evidence exists regarding their risks and benefits in this population. This retrospective cohort study examines the association between antithrombotic therapy and mortality in older patients with hip fracture. DESIGN: Retrospective cohort study. SETTING AND PARTICIPANTS: Patients with hip fracture admitted to a level 1 trauma center between January 2021 and December 2022. METHODS: Data on clinical characteristics, antithrombotic therapy, and outcomes were collected from health records. Mortality was analyzed using Kaplan-Meier curves and Cox proportional hazards regression, adjusting for age, sex, comorbidity, functional status, surgery, kidney function, body mass index, and nursing home residency. Secondary outcomes included transfusion rates and thromboembolic events. RESULTS: Among 526 patients (median age, 82 years; 69% female), 1-year mortality rates were 14.3% for no antithrombotic therapy, 21.0% for antiplatelet therapy, 26.4% for DOACs, and 48.9% for VKAs. At 2 years, mortality rates increased to 20.9%, 30.4%, 32.1%, and 61.7%, respectively (log-rank P < .001). In the fully adjusted model, the mortality risks associated with antiplatelet therapy [hazard ratio (HR), 0.71; 95% CI, 0.45-1.12] and DOACs (HR, 0.99; 95% CI, 0.54-1.81) were no longer significant compared with patients without antithrombotic therapy, whereas VKAs remained significantly associated with increased mortality (HR, 2.17; 95% CI, 1.22-3.83). Secondary outcomes revealed that all antithrombotic therapies were linked to delayed surgery and higher transfusion rates. However, neither delayed surgery nor transfusions independently predicted mortality. CONCLUSIONS AND IMPLICATIONS: VKA use is associated with significantly higher mortality in older patients with hip fracture and may identify a subset at substantial risk of poor outcomes. These findings underscore the need for careful assessment and management of VKA users and further research to confirm these observations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of General Internal Medicine, Department of Internal Medicine, Section Geriatric Medicine, Maastricht University Medical Center+, Maastricht, the Netherlands.
- Thrombosis Expert Center Maastricht, Department of Internal Medicine, Section of Vascular Medicine, Maastricht University Medical Center+, Maastricht, the Netherlands; CARIM School for Cardiovascular Disease, Maastricht…
- Department of Orthopedic Surgery, Maastricht University Medical Center+, Maastricht, the Netherlands.
- Department of Trauma Surgery, Maastricht University Medical Center+, Maastricht, the Netherlands.
- Department of Vascular Medicine, Amsterdam University Medical Center, Amsterdam, the Netherlands.
- Department of Vascular Medicine, Amsterdam University Medical Center, Amsterdam, the Netherlands; Diabeter Center Amsterdam, Amsterdam, the Netherlands.
Zitieren
APA
Vleeshouwers, K., Bastings, J. J. C., Brüggemann, R., de Jong, M. J., van den Boogaart, M., Poeze, M., van Es, N., Hanssen, N. M. J., Brouns, S., Magdelijns, F., & Spaetgens, B. (2025). Antithrombotic Therapy and Mortality Risk in Older Adults with Hip Fractures. Journal of the American Medical Directors Association. https://doi.org/10.1016/j.jamda.2025.105690
Vancouver
Vleeshouwers K, Bastings JJC, Brüggemann R, de Jong MJ, van den Boogaart M, Poeze M, et al. Antithrombotic Therapy and Mortality Risk in Older Adults with Hip Fractures. Journal of the American Medical Directors Association. 2025. doi:10.1016/j.jamda.2025.105690
BibTeX
@article{Vleeshouwers2025,
author = {Vleeshouwers, Karin and Bastings, Janneke J C and Brüggemann, Renée and de Jong, Melanie J and van den Boogaart, Mark and Poeze, Martijn and van Es, Nick and Hanssen, Nordin M J and Brouns, Steffie and Magdelijns, Fabienne and Spaetgens, Bart},
title = {Antithrombotic Therapy and Mortality Risk in Older Adults with Hip Fractures},
journal = {Journal of the American Medical Directors Association},
year = {2025},
doi = {10.1016/j.jamda.2025.105690}
}
EUVIMED